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Background: Reovirus exploits aberrant signalling downstream of Ras to mediate tumor-specific oncolysis. Since
~90% squamous cell carcinomas of the head and neck (SCCHN) over-express EGFR and SCCHN cell lines are
sensitive to oncolytic reovirus, we conducted a detailed analysis of the effects of reovirus in 15 head and neck
cancer cell lines. Both pre- and post-entry events were studied in an attempt to define biomarkers predictive of
sensitivity/resistance to reovirus. In particular, we analysed the role of EGFR/Ras signalling in determining
virus-mediated cytotoxicity in SCCHN.
Methods: To test whether EGFR pathway activity was predictive of increased sensitivity to reovirus, correlative
analyses between reoviral IC50 by MTT assay and EGFR levels by western blot and FACS were conducted.
Inhibition or stimulation of EGFR signalling were analysed for their effect on reoviral oncolysis by MTT assay, and
viral growth by TCID50 assay. We next analysed the effects of inhibiting signalling downstream of Ras, by specific
inhibitors of p38MAPK, PI3-K or MEK, on reoviral killing examined by MTT assay. The role of PKR in reoviral killing
was also determined by blockade of PKR using 2-aminopurine and assaying for cell survival by MTT assay. The
apoptotic response of SCCHN to reovirus was examined by western blot analysis of caspase 3 cleavage.
Results: Correlative analyses between reoviral sensitivity and EGFR levels revealed no association. Intermediate
sub-viral and core particles showed the same infectivity/cytotoxicity as intact reovirus. Therefore, sensitivity was not
determined by cell entry. In 4 cell lines, oncolysis and viral growth were both unaffected by inhibition or
stimulation of EGFR signalling. Inhibition of signalling downstream of Ras did not abrogate reoviral oncolysis and, in
addition, modulation of PKR using 2-aminopurine did not alter reovirus sensitivity in resistant cell lines. Caspase 3
cleavage was not detected in infected cells and oncolysis was observed in pan-caspase inhibited cells.
Conclusions: In summary, reovirus is potently oncolytic in a broad panel of SCCHN cell lines. Attempts to define
sensitivity/resistance by analysis of the EGFR/Ras/MAPK pathway have failed to provide a clear predictive biomarker
of response. Further analysis of material from in vitro and clinical studies is ongoing in an attempt to shed further
light on this issue.
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Reovirus is a small, non-enveloped double-stranded
RNA virus, commonly isolated from the human respira-
tory or gastrointestinal tract [1]. Infection is widespread,
with 50-100% of adults showing seropositivity [2,3].
However, reovirus is considered benign because most
infections are either asymptomatic or result in only mild
illness. Despite its lack of pathogenicity in humans, reo-
virus displays selective oncolytic activity against trans-
formed and malignant cells [4,5]. Initial mechanistic
studies showed that transfection with elements of the
Ras signalling pathway, including EGFR and its constitu-
tively active form v-erbB, sos and mutated Ras itself,
increased the sensitivity of cells to reovirus-induced cell
death [6,7]. The activated Ras signalling in these cells
was subsequently found to inhibit the function of PKR,
which in untransformed cells prevents viral protein
translation. Thus, in Ras-activated cells, dysfunctional
PKR signalling allows reovirus replication to proceed
and cell death ensues [7,8].
Evidence from several studies into the precise molecu-
lar interactions linking increased Ras pathway activity
and the regulation of reovirus oncolysis reveals a com-
plex picture. NIH-3T3 fibroblast cells, transformed with
activated forms of Ras, only supported reovirus replica-
tion if signalling from Ras to RalGEF/p38MAPK was in-
tact [9]. When p38MAPK was inhibited in melanoma,
reovirus-induced oncolysis was abrogated [10]. Together,
this indicates that activity in the p38MAPK pathway is a
determinant of sensitivity to reovirus in these cell types.
Alternatively, in C26 colorectal tumour cells, reovirus-
induced cell death was found to be distinct from Ras sta-
tus and viral replication. In either the presence or ab-
sence of mutant Ras, C26 cells supported reovirus
replication but expression of mutated Ras increased the
sensitivity of tumour cells to reovirus-induced apoptosis
[11]. Additional influences of Ras pathway status on the
effects of reovirus infection have been highlighted by
Marcato et al. (2007) who demonstrated significantly
enhanced proteolytic disassembly (uncoating) of reovirus
in Ras-transformed NIH-3T3 cells [12]. They also
showed that Ras transformation increases the infectious:
non-infectious particle ratio and promotes caspase-
mediated release and spread of viral progeny.
In spite of differences in the reported mechanism of
killing, preclinical studies in a wide range of in vitro and
in vivo models, including intratumoural and intravenous
injections in immune-deficient and -competent mice,
have clearly shown that reovirus has a broad spectrum
of oncolytic activity (reviewed in [13,14]). Clinical testing
of reovirus through a strong translational programme is
well advanced following phase I and II studies as a single
agent [15-17] and in combination with cytotoxic chemo-
therapy [18-20] or radiotherapy [21]. Consequently,reovirus is currently being tested under a Special Proto-
col Agreement from the US Federal Drug Administra-
tion in a randomised phase III study of carboplatin and
paclitaxel plus either placebo or reovirus in patients with
relapsed/metastatic SCCHN (http://clinicaltrials.gov/ct2/
show/NCT01166542).
Overexpression of epidermal growth factor receptor
(EGFR) and consequent activation of the Ras signalling
pathway is the dominant oncogenic process in SCCHN
[22]. Specific anti-EGFR monoclonal antibodies have
already shown clinical benefits in newly diagnosed [23]
and relapsed/metastatic SCCHN [24] and it is likely that
novel agents that target the EGFR/Ras axis will be active
in this disease. Therefore, we have conducted a detailed
analysis of the effects of reovirus in a panel of head and
neck cancer cell lines. Both pre- and post-entry events
have been studied in an attempt to define biomarkers
that will predict for sensitivity/resistance to reoviral ther-
apy. In particular, we have analysed the role of the
EGFR/Ras signalling pathway in determining virus-
mediated cytotoxicity in SCCHN.
Results
Reovirus is active against a panel of head and neck
cancer cell lines
We initially sought to profile and define the sensitivity
of human head and neck (SCCHN) tumour cells to
reovirus-induced oncolysis. A panel of 15 previously
characterised cell lines [25] were infected with serial
dilutions of reovirus and assessed for cell survival. The
SCCHN tumour cell lines showed a broad range of sen-
sitivities to reovirus (Figure 1A, B). Using these data, the
IC50 dilution of reovirus for each cell line was derived
and the resulting values ranked (Figure 1C). HN3 and
HN5 were chosen as examples of relatively resistant cell
lines, with IC50 dilutions of 3.0 × 10
-4 and >2 × 10-3,
respectively, whereas Cal27 (1.2 × 10-6) and SIHN-5B
(1.5 × 10-6) were selected as relatively sensitive to reo-
virus. These cell lines were used in many of the subse-
quent experiments in view of our previous experience of
their reliable in vitro behaviour.
The method of reoviral entry into SCCHN cells does not
predict their sensitivity
The main cellular receptor for reovirus is the junctional
adhesion molecule-1 (JAM-1) [26]. Therefore, the level
of JAM-1 expression was determined by FACS analysis
on 4 representative cell lines with a spread of IC50 values
of approximately 3 logs. JAM-1 expression was lowest in
the most resistant cell line (HN5). However, HN5 cells
still expressed measurable levels of JAM-1 and the high-
est level of receptor expression was seen in the second
most resistant cell line (HN3). Overall, there was no
clear evidence that the level of JAM-1 expression
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Figure 1 HN cell lines have a wide range of reovirus IC50 dilution values. A, B. HN cells were infected with reovirus at 1.4×10
9 TCID50/ml
diluted 2 fold, starting from a 1:500, a 1:1000 or a 1:5000 dilution. Cell survival was assessed by MTT assay at 96 hours post-infection. Data were
log transformed and plotted as sigmoidal dose response curves, with uninfected controls assigned an arbitrary value of 1×10-8. Means are from 3
independent experiments and error bars represent SEMs. C. IC50 dilutions of reovirus were interpolated from the dose response curves.
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induced cell death (Additional file 1).
Before reovirus can access the cytoplasm, capsid proteins,
notably σ3 and μ1, are removed or altered by proteolysis
[27,28]. This occurs either within endosomes or lysosomes
following receptor binding and endocytosis of intact viral
particles, or by extracellular digestion creating an inter-
mediate or infectious subviral particle (ISVP), which can
penetrate the membrane and enter the cytoplasm directly.
Since Ras-transformed cells can secrete proteases, we inves-
tigated whether predigestion of reovirus particles could en-
hance their infectivity in SCCHN cells. In particular, we
wished to test whether predigested reovirus would be more
cytotoxic in the relatively resistant HN5 cell line.
Reovirus was treated at 37°C with chymotrypsin for ei-
ther 5 mins to form ISVPs or 1 hour to give core particles.
These digestion conditions were verified by the disappear-
ance of λ, μ and σ proteins, detected by western blot
(Figure 2A). Infection with ISVP and viral cores showed
the same level of cytotoxicity in Cal27 cells as with un-
digested reovirus (Figure 2B). In HN5, the digested parti-
cles were impaired very slightly in their infectivity at the
highest concentration at which they were exposed to thecells, but exhibited the same level of cell kill as untreated
reovirus at all other dilutions (Figure 2C). These data
demonstrate that generation of ISVPs through pre-entry
proteolysis does not influence sensitivity to reovirus in
SCCHN cells. Therefore, we next sought to investigate the
intracellular interactions taking place during reovirus in-
fection in this tumour type.
Characterisation of EGFR expression in the SCCHN cell
panel
The dependence of reovirus oncolysis on upregulated
Ras signalling has been reported previously [7,8]. Since
Ras signalling can be driven by EGFR stimulation and
SCCHN overexpresses EGFR, the panel of cell lines was
evaluated for EGFR expression levels with a view to
assessing whether reovirus sensitivity could be predicted
by measuring EGFR expression. FACS analysis of EGFR
expression was carried out for the whole panel and 9
representative cell lines were also profiled for total and
phospho-EGFR by western blot. A broad range of cell
surface EGFR levels was evident across the panel
(Figure 3A). Similarly, total and phospho-EGFR protein
levels were also widely distributed in the cell lines tested
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Figure 2 Reovirus ISVPs and cores kill HN cells to the same extent as intact virus. A. Reovirus stocks at 7.8×108 TCID50/ml were treated
with 10μg/ml chymotrypsin (CHT) for times and temperatures indicated. Viral proteins were resolved on 10% NuPage Novex Bis Tris gels and
probed using reovirus goat anti-serum. B, C. Reovirus treated for 5 mins (ISVPs) or 1 hr (cores) at 37°C, was used to infect Cal27 (B) and HN5 (C)
cells, alongside un-digested reovirus. Cell survival was assessed by MTT assay at 96 hours post-infection. Means are from 3 independent
experiments and error bars represent SEMs.
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Cal27 (median fluorescence value 1049) expressed the
highest amounts of EGFR by FACS and western blot.
Conversely, HN3 and SIHN-5B have relatively low levels
of surface EGFR (median fluorescence 193 and 7, re-
spectively). Levels of total and phospho-EGFR for SIHN-
5B were undetectable by western blot, while HN3 had
constitutively phosphorylated EGFR. Following profiling,
the cell lines were ranked according to their EGFR ex-
pression by FACS and western analysis for either total or
phospho-EGFR - resulting in 3 different ranks (Additional
file 2: Table S1). To determine whether the FACS data
correlate with total and/or phospho-EGFR, the ranked
data were plotted against each other. FACS data vs total
EGFR western blot showed a strong positive correlation
(R2 = 0.90, P < 0.001) (Additional file 3). No correlation
was evident between FACS analysis and phospho-EGFR
western blot (R2 = 0.22, P = 0.58) (Additional file 4), reveal-
ing that surface level EGFR analysis represents the levels
of total EGFR protein in each cell line, rather than the ac-
tive signalling component.Correlation between EGFR expression, GTP-loading on
Ras and reovirus sensitivity
To test whether EGFR pathway activity, and, hence, sig-
nalling in the Ras pathway, was predictive of increased
sensitivity to reovirus, the EGFR ranks obtained in
Figure 3A and B were plotted against the ranks of reo-
virus IC50 dilution derived for the cell line panel
(Figure 1C). Total EGFR assessed either by FACS or
western blot did not correlate with reovirus IC50 dilution
(Figure 3C, D (R2 = 0.13, P > 0.1 and −0.43, P > 0.1, re-
spectively). Interestingly, a non-statistically significant
inverse correlation was seen between phospho-EGFR
and reovirus IC50 dilution (Figure 3E) (R
2 =−0.67,
P = 0.06).
The baseline GTP-loading status of Ras was deter-
mined for 12 representative cell lines. The resulting
western blot (Figure 4A) and densitometry data
(Figure 4B) demonstrate that most cell lines had similar
levels of Ras activation. Exceptions to this finding
included SIHN 013, PJ41 and PJ34 cell lines. There was
no significant correlation between Ras activation status
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Figure 3 HN cell lines show varying EGFR expression levels. A. HN cells were stained with anti-EGFR primary antibody (7.5 μg/ml ICR62) then
with 20 μg/ml FITC conjugated secondary antibody. Median fluorescence was determined by FACS analysis. Means are from at least 2
independent experiments and error bars represent SEMs. B. Lysates of HN cells indicated were analysed on 10% Precise Protein Gels and
subsequently probed for total EGFR, phospho-Tyr1068 EGFR and α-tubulin for loading control. C, D, E. Reovirus IC50 dilutions were assigned rank
values (1 = resistant, 15 = sensitive) and were correlated against ranked (C) median fluorescence levels, (D) ranked densitometry values for total
EGFR or (E) phospho-tyr1068 EGFR (1 = EGFR low, 9 = EGFR high). R2 = 0.13, -0.43 and −0.67 respectively.
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tion) (Figure 4C).
For further experiments, 4 cell lines were selected
from the panel as being representative of the broad
range of EGFR expression/reovirus sensitivity: HN5
(EGFR high, reovirus resistant); HN3 (EGFR low, reo-
virus resistant; Cal27 (EGFR high, reovirus sensitive);
and SIHN 5B (EGFR low, reovirus sensitive).
Epidermal Growth Factor Receptor stimulation or
blockade does not affect reoviral cytotoxicity or growth
We next examined whether manipulation of EGFR sig-
nalling could change the sensitivity of the 4 selected cell
lines to reovirus by stimulating or blocking the receptor,
infecting cells with virus and measuring cell survival
(Figure 5A-E, Additional file 5, Additional file 6,
Additional file 7). Pre-treatment with EGF did not alter
cell survival post-reovirus infection in all 4 cell lines
(P > 0.1), although treatment with EGF alone was mark-
edly cytotoxic to HN5 (Additional file 7). Blockade of the
receptor using an anti-EGFR antibody to inhibit ligandbinding (ICR62) [29] or using tyrosine kinase inhibitors to
inactivate the signalling capability of the receptor (Iressa/
Gefitinib or Tyrphostin-AG99) also had no effect on cell
survival following infection with reovirus (P > 0.1 for all
analyses). The activity of the EGFR inhibitors was tested
in the context of stimulation by EGF (Additional file 8).
Both ICR62 and Iressa/Gefitinib effectively inhibited phos-
phorylation of EGFR, but Tyrphostin-AG99 was inactive.
HN5 exhibited a previously documented sensitivity to
Iressa/Gefitinib [30].
It has been reported that activated Ras signalling
blocks the anti-viral action of PKR and permits
increased reoviral replication [7,8]. Therefore, we tested
the effect of EGFR stimulation and inhibition on reoviral
growth. Cells were pre-incubated with EGF, ICR62 or
media alone and then infected with reovirus. At various
time points after infection the cells and their superna-
tants were harvested and titred by TCID50 assay. Neither
stimulation by EGF nor inhibition by ICR62 affected the
growth of reovirus in the 4 cell lines tested (Figure 6A-D).
This result was further confirmed using gefitinib/iressa
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showed the same level of reoviral replication, despite their
differing susceptibility to reovirus-induced cell death indi-
cating that high or low replication rates do not account
for the range of reovirus sensitivities observed (Additional
file 10).
Reovirus cytotoxicity does not depend on PI3-K, MAPK or
p38MAPK signalling
Having examined the influence of EGFR itself on reo-
viral oncolysis in SCCHN, we went on to determine
whether inhibition of downstream signalling effectors
could influence sensitivity to reovirus. We targeted the
three major signalling pathways downstream of Ras -
MAPK, PI3-K and p38MAPK. To inhibit MEK in the
MAPK pathway, the specific tyrosine kinase inhibitors
PD184352 (PD) and U0126 (U) were used [31,32]. PD
was employed at 2 different concentrations, 2 μM to tar-
get MEK1/2 only and 10 μM for blockade of MEK1/2
and MEK5. LY294002 (LY) and wortmannin (wort) were
utilised to block PI3-K [33], and p38MAPK was inhib-
ited by SB202190 (SB) [34]. Following incubation with
inhibitors, cells were infected with reovirus and cell sur-
vival was analysed. Inhibitor activity was confirmed by
western analysis for all pathways except p38MAPK,
where the many isoforms of p38MAPK makes this type
of analysis unsuitable. Instead, we confirmed p38MAPK
blockade by SB by means of ELISA. Reoviral cytotoxicity
in SCCHN was not abrogated by blockade in any of the3 pathways tested, with cell survival being equal to or
less than reovirus infection alone (Figure 7A-F,
Additional file 11, Additional file 12, Additional file 13)
(P > 0.05 for all analyses). For p38MAPK inhibition by
SB, in all cell lines the agent had little single agent cyto-
toxic activity and did not reduce reovirus-induced cell
kill. For PI3K inhibition, LY induced significant cell
death in 3 of the 4 cell lines (Figure 7, Additional file 11
and 12) but this was not the case with wortmannin.
Again, there was no evidence that either LY or wortman-
nin was capable of abrogating the cytotoxicity of
reovirus.
However, for the analyses involving PD184352, it was
clear that this agent exerted significant single agent ac-
tivity at both 2 and 10 μM concentration and this raised
concerns that this effect might have masked an inhibi-
tory effect on reovirus cytotoxicity. Thus, we decided to
subject the combination of reovirus and PD184352 to
formal combination index analysis according to the
methodology of Chou and Talalay [35]. Initially, we
defined IC50 values for PD184352 in SIHN-5B, Cal27,
HN3 and HN5 cells (data not shown) and then com-
bined fixed ratios (0.5, 1.0 and 2.0 IC50) of the IC50 of
reovirus and PD184352 and analysed cell survival by
MTT assay as described previously. These data demon-
strated striking synergy between reovirus and MEK in-
hibition for all cell lines (Additional file 14).
Therefore, taken together, these data suggest that un-
like earlier observations made in transformed fibroblasts,
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Figure 5 Stimulation or inhibition of EGFR signalling does not affect reovirus cytotoxicity in Cal27 cells. Cells were treated for 1 hr with
200 nM epidermal growth factor (EGF), 400nM anti-EGFR antibody (ICR62), 1 μM Iressa or 100 μM Tyrphostin AG99 (Tyrp), then either lysed,
resolved on 8% Precise Protein Gels and probed for total EGFR, phospho-Tyr1068 EGFR and GAPDH or α-tubulin as loading controls, or infected
with reovirus at 1.9×109 TCID50/ml and assayed for cell survival by MTT at 96 hours post-infection. Reovirus was diluted as follows: 1:16000 (20%),
1:4000 (50%) and 1:500 (80%). A. EGF stimulation does not increase reoviral cytotoxicity. B, C, D. ICR62-, gefitinib- (Iressa) and Tyrphostin-mediated
inhibition of EGFR did not inhibit reoviral cytotoxicity. Means are calculated from 3 independent experiments and error bars represent SEMs. E.
Western blot analysis showing effect of EGF, ICR62, Gefitinib (Iressa) and Tyrphostin on EGFR signaling.
Twigger et al. BMC Cancer 2012, 12:368 Page 7 of 16
http://www.biomedcentral.com/1471-2407/12/368reoviral cytotoxicity is not dependent on the activation
of downstream effectors of Ras in SCCHN. In fact, reo-
virus appears to show a surprising synergistic interaction
with MEK inhibition across all 4 cell lines tested when
the agents are combined at ratios close to the IC50.
Pharmacological inhibition of PKR phosphorylation does
not restore reovirus sensitivity to resistant cells
Transformation of reovirus resistant fibroblasts with
intermediates of the EGFR and Ras signalling pathway
was previously shown to inactivate PKR and, thereby,
allow viral protein synthesis to proceed [7]. To deter-
mine the role of PKR in reoviral killing in SCCHN, 4relatively reovirus-resistant cell lines were incubated
with 2-AP then infected and assayed for cell survival. Al-
though the presence of 2-AP marginally increased cyto-
toxicity in 3 of the cell lines, the effect did not reach
statistical significance (SIHN-11B (Figure 8A, P = 0.068),
PJ41 (Figure 8B, P = 0.14), HN3 (Figure 8C, P = 0.07) or
HN5 (Figure 8D, P = 1.0)). These data suggest that the
oncolytic effect of reovirus in these cells is not con-
trolled by PKR inactivation. 2-AP had no effect on reo-
viral cytotoxicity in the sensitive Cal27 cell line (data not
shown).
Given the fact that these findings do not mirror previ-
ously reported findings in transformed NIH-3T3 cells
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Figure 6 Reovirus grows at the same rate in EGFR-stimulated or -inhibited SCCHN cells as in untreated cells. A. Cal27, B. SIHN 5B, C. HN3
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times indicated for TCID50 titration on L929 cells. Means are from at least 2 independent experiments and error bars represent SEMs.
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http://www.biomedcentral.com/1471-2407/12/368[7], we analysed the effect of reovirus infection and 2-AP
treatment on L929 cells and the 4 relatively reovirus-
resistant head and neck cancer cell lines using immuno-
cytochemistry to measure p-PKR staining and western
analysis to define downstream phosphorylation of EIF2α
(which acts to inhibit viral protein translation). In L929
cells, reovirus infection had little effect on p-PKR
staining or p-EIF2α protein levels, although 2-AP
reduced both of these signals in the absence or presence
of reovirus infection, confirming activity of the drug
(Additional file 15, Figure 8E). Similarly, both at the level
of immunocytochemistry (Additional file 15) and (more
variably) on western analysis (Figure 8E), 2-AP was
shown to reduce the p-PKR and p-EIF2α signal as a sin-
gle agent therapy, confirming drug-on-target effect for
this agent. Interestingly, in 3 of the 4 head and neck can-
cer cell lines, reovirus infection increased p-PKR staining
(Additional file 15) and this was not reversible with 2-
AP. p-EIF2α remained unchanged or increased in re-
sponse to reovirus infection in all 4 head and neck can-
cer cell lines and was only reduced by 2-AP in PJ41 cells
(although this did not correlate with increased reovirus
cytotoxicity). In fact, the western analysis data from PJ41
cells more closely resembled those from L929 cells.
Taken together, these data demonstrate that although 2-
AP is biologically active in uninfected reovirus-resistanthead and neck cancer cell lines, it does not prevent
reovirus-induced phosphorylation of PKR and down-
stream phosphorylation of p-EIF2α and does not in-
crease reovirus-induced cytotoxicity.Interferon signalling does not predict reovirus sensitivity
In view of the fact that many viruses trigger innate im-
mune activation, the profile of interferon secretion be-
fore and after reovirus infection was determined in
Cal27, HN3, HN5 and SIHN-5B cells by ELISA assay for
interferon-α, -β and γ Additional file 16). In the unin-
fected state, there was no clear correlative pattern be-
tween reovirus sensitivity and baseline interferon
secretion, which was limited to interferon-β. For ex-
ample, the most resistant cell line (HN5) had unmeasur-
able basal secretion of interferon-α, -β and γ whereas
the next most resistant cell line (HN3) secreted the
highest levels of interferon-β. In response to reovirus in-
fection, interferon secretion (mainly interferon-β) was
increased in Cal27, HN5 and SIHN-5B cell lines, but the
pattern did not correlate with sensitivity to reovirus.
Thus, although the lowest level of interferon-β signalling
was seen in the most sensitive cell line (Cal27), the high-
est level of interferon-α and –β signalling was seen in
the next most sensitive cell line (SIHN-5B).
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Figure 7 MEK, PI3-K or p38MAPK inhibition does not affect reovirus cytotoxicity. Cal27 cells were inhibited for 2 hrs with 2 μM (PD2) or 10
μM (PD10) PD184352, 10 μM U0126 (U), 10 μM SB202190 (SB), 10 μM LY294003 (LY) or 1 μM wortmannin (wort). Monolayers were then either
lysed, resolved on 8% Precise Protein Gels (MAPK) or 10% NuPage Novex Bis Tris gels (PI3-K) and probed for total ERK1/2, phosho-Thr202 ERK1/2,
total AKT, phospho-Ser473 AKT and GAPDH or β-actin as loading controls, or infected with reovirus at 1.2×1010 TCID50/ml (PD, SB and LY) or
7.8×108 TCID50/ml (wort) and assayed for cell survival by MTT. p38MAPK target knock-down was confirmed by ELISA. Reovirus was diluted at
1:4000 for 50% cell kill. A, B. MAPK inhibition. C, D. p38MAPK inhibition. E, F. PI3K inhibition. Means are calculated from at least 3 independent
experiments and error bars represent SEMs.
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http://www.biomedcentral.com/1471-2407/12/368Reovirus-induced cell death is not apoptotic in SCCHN
Previous reports have suggested that for some cells the ef-
fect of Ras activation on reoviral cytotoxicity might be
mediated by sensitising the cells to virally-induced apop-
tosis, rather than determining their ability to support viral
replication. Our finding that both resistant and sensitive
SCCHN cells support reovirus replication to the same ex-
tent (Additional file 10) raises the possibility that this ef-
fect may also be operating in SCCHN. Therefore, the
apoptotic response of SCCHN to reovirus was examined
by western blot analysis of caspase 3 cleavage. Jurkat cells
treated with 10 μM camptothecin were used as a positive
control and showed the 19kDa caspase 3 cleavage product
(Figure 9A). In contrast, reovirus did not induce apoptosis
in the 4 SCCHN cell lines tested (Figure 9A).
This result was confirmed by incubating SCCHN cells
with the pancaspase inhibitor z-VAD-FMK (ZVAD), prior
to reovirus infection or treatment with the exogenous
apoptosis-inducing ligand TRAIL (as a positive control),and measuring cell survival. Varying responses to reovirus
and TRAIL were observed in the different cell lines. Specif-
ically, TRAIL treatment was associated with reduced cell
survival in 3 of the 5 SCCHN cell lines tested and in all
cases ZVAD was effective in partially reversing cytotoxicity.
TRAIL reduced cell survival in Cal27 and this was inhibited
by ZVAD treatment. However, the level of reovirus-induced
cell kill was similar in the presence or absence of ZVAD
(P>0.1) (Figure 9B). Pre-incubation of SIHN 5B with
ZVAD also abrogated TRAIL-induced cytotoxicity, but reo-
virus oncolysis was also non-statistically significantly inhib-
ited by ZVAD treatment (P=0.1) in these cells (Figure 9C).
HN3 cells were resistant to the effects of TRAIL and
reovirus-induced cell kill was unaffected by the presence of
ZVAD (P>0.1) (Figure 9D). HN5 cells were extremely sen-
sitive to TRAIL-induced apoptosis, which was almost fully
reversed by treatment with ZVAD. However, as observed
above, this cell line was largely resistant to reovirus and this
was not altered by ZVAD treatment (P>0.1) (Figure 9E). In
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http://www.biomedcentral.com/1471-2407/12/368contrast, 011A were completely insensitive to TRAIL and
highly sensitive to reovirus-induced cell death, but this was
not affected by pre-incubation with ZVAD (P>0.1)
(Figure 9F). Taken together, these results indicate that
reovirus-induced cell death in SCCHN cells does not in-
volve caspase 3 activation and is not inhibited by pancas-
pase blockade. Therefore, in marked contrast to melanoma
cell lines [36], reovirus killing of SCCHN cells appears to be
non-apoptotic.Discussion
The translational development of reovirus has progressed
at a rapid rate through a series of phase I and II clinical
trials that have been driven by an active programme of
preclinical research (reviewed in [37]). Reovirus has been
shown to be active against a wide variety of tumour types
and to mediate synergistic therapeutic interactions with
either chemotherapy [18,19,38,39] or radiotherapy [21,40].
As a result of this work, reovirus is currently being tested
in combination with carboplatin-paclitaxel doubletchemotherapy in a phase III study in patients with platin-
refractory SCCHN.
The initial studies on the mechanism of reovirus-
induced killing of tumour cells suggested that Ras path-
way activation (by oncogenic mutation or upstream
dysregulation) was a key determinant of viral replication
and subsequent oncolysis [6,7]. This raised the prospect
of using Ras mutation or pathway activation status as a
biomarker to guide patient selection for reovirus therapy
in clinical studies. However, further mechanistic studies
have shown that the situation is highly complex and, as
yet, no definitive biomarker of sensitivity to reovirus has
been defined. Therefore, in most ongoing studies of
oncolytic reovirus, the state of activation of the EGFR/
Ras axis is not used as an entry requirement or as a
stratification factor. Since SCCHN has emerged as an
extremely important clinical target for oncolytic reovirus
therapy, we undertook a detailed analysis of the factors
that might predict sensitivity to treatment in SCCHN
with a view to defining predictive biomarkers for testing
in future clinical studies. In particular, our initial
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Figure 9 Reovirus induced cell death is not apoptotic in SCCHN cells. A. SCCHN cells shown were infected with reovirus (MOI 1) using viral
stocks at 3.7×109 TCID50/ml and Jurkat cells were treated with 10 μM camptothecin (campto). Lysates were resolved on 10% NuPage Novex Bis
Tris gels and probed for pro-caspase 3 cleavage. B. Cal27, C. SIHN 5B, D. HN3, E. HN5 and F. 011A were treated with pan-caspase inhibitor (ZVAD,
200 μM) for 2 hr prior to either TNFα-related apoptosis inducing ligand treatment (TRAIL 100ng/ml) or reovirus infection (MOI 10) using viral
stocks at 1.9 × 109 TCID50/ml. Cell survival was assessed by MTT assay at 96 hours post-infection. Means are from at least 3 independent
experiments and error bars represent SEMs.
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http://www.biomedcentral.com/1471-2407/12/368hypothesis was that the sensitivity of SCCHN to reovirus
would largely depend on the signalling status in the
EGFR/Ras/MAPK axis.
In initial studies, we profiled the relative sensitivities
of a panel of 15 SCCHN cell lines and saw a 5-log range
in IC50 (Figure 2A, B). Subsequent analysis of EGFR ex-
pression by flow cytometry (in 15 cell lines) and by
western analysis for total and phospho-EGFR (in 9 cell
lines) showed significant variability between individual
SCCHN cell lines (Figure 3A, B), but no statistically sig-
nificant correlations with reovirus sensitivity (Figure 3C-
E). Indeed, if anything, there was a trend towards a
negative correlation between phospho-EGFR on western
analysis and reovirus sensitivity by IC50 estimation
(Figure 3E). Further studies in which we quantitated
GTP-loading on Ras (Figure 4) and modulated signalling
through the EGFR/Ras/MAPK axis (Figures 5, 6, 7,
Additional file 5, Additional file 6, Additional file 7,
Additional file 9, Additional file 11, Additional file 12,
Additional file 13) failed to provide a clear indication of
a cellular marker of sensitivity or resistance to reovirus.Indeed, it is interesting to note that the extent of in vitro
reoviral replication did not correlate with cytotoxicity in
SCCHN cells. In this respect, the data are similar to
those obtained in other studies using C26 colorectal
tumour cells but, in direct contrast to those findings, the
mechanism of death in SCCHN cells was non-apoptotic
(Figure 9).
Therefore, despite clear evidence that there can be sig-
nificant variability (> 5 logs) in the susceptibility of
SCCHN to reovirus-induced cytotoxicity, detailed profil-
ing of pre- and post-entry events has failed to define a
clear signaling biomarker (or combination of biomar-
kers) of sensitivity or resistance. These findings have a
number of implications. Most importantly, it is clear
that, at least at the present time, an attempt to select
SCCHN patients for oncolytic reovirus therapy on the
basis of putative biomarkers in the EGFR/Ras/MAPK
pathway is not a viable strategy. In regard to the ongoing
phase III study in patients with relapsed/metastatic head
and neck cancers, our data provide reassurance that the
eligibility criteria that allow entry of patients with platin-
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http://www.biomedcentral.com/1471-2407/12/368refractory disease, irrespective of EGFR/Ras/MAPK
pathway status, are appropriate. We cannot exclude the
possibility that EGFR/Ras signaling may ultimately have
some significant predictive value for reovirus therapy in
SCCHN, especially in the light of the extensive intercon-
nectivity and redundancy of signaling pathways within
tumour cells. This would be consistent with findings in
other oncolytic systems in which early indications of
specific genetic dependencies for oncolytic specificity
turned out to be more complex than initially thought
[41]. In addition, our studies here focus exclusively upon
the genetic determinants of reovirus replication in
tumour cells in culture. It is well established that sensi-
tivity to viral replication and cytolysis in vitro can some-
times bear little relation to in vivo sensitivity of a
tumour type, especially in the context of immunocompe-
tent models [42]. We profiled innate immune response
(at baseline and in response to viral infection) in 4 repre-
sentative SCCHN cell lines and saw no clear correlation
with reovirus sensitivity (Additional file 16). However,
the screens that we have performed here do not take
into account the dependence of innate immune
responses to viral infection, in both tumor cells and host
immune effectors, upon cell signaling pathways, such as
EGFR/Ras, in the tumour cells. Therefore, it is possible
that many components of the complex relations between
sensitivity to reovirus infection, replication, cytolysis and
tumor therapy remain to be elucidated.
Looking forwards, our in vitro findings provide a strong
rationale for collecting tumour samples from the patients
currently enrolling in clinical protocols as a driver for fur-
ther biomarker discovery studies. It will be especially use-
ful to obtain pre- and post-treatment samples from the
large number of patients entering the reovirus clinical
programme and to correlate findings from genomic, tran-
scriptomic and proteomic studies on tumour and normal
tissues with the clinical outcome data. Indeed, we are cur-
rently adopting this approach across a broad panel of
tumour cell types in in vitro analyses to provide guidance
for the use of precious patient samples obtained in on-
going and future clinical studies with reovirus.
In the setting of SCCHN, it is also useful to interpret
our data in the context of similar attempts to define bio-
markers for treatment response to anti-EGFR-targeted
monoclonal antibodies, such as cetuximab/erbitux, zalu-
tumumab and panitumumab [43]. Despite our ability to
design chimeric, humanised or fully human antibodies
with exquisite selectivity for a precisely designed target
(EGFR) and the clear demonstration that these agents
mediate a therapeutic effect in SCCHN, we are appar-
ently no closer to defining biomarkers to predict which
patients with this disease will and will not respond to
anti-EGFR monoclonal antibody targeted therapy. This
fact most likely highlights both the complexity ofinterplay between elements of the downstream signalling
pathways and the limitations of trying to fully define the
pathway by studying one element at a time. If this is true
for a relatively simple biologic such as a monoclonal
antibody, perhaps we should not be surprised that the
same is true for a complex, multi-faceted agent like an
oncolytic virus.
Conclusions
In summary, we have shown that reovirus is potently
oncolytic in a broad panel of SCCHN cell lines.
Attempts to define sensitivity/resistance by analysis of
the EGFR/Ras/MAPK pathway have failed to provide a
clear predictive biomarker. Further analysis of material
from in vitro and clinical studies is ongoing in an at-
tempt to shed further light on this issue.
Methods
Cells
Detroit-562, Cal27, 006/1, 005A, 013, HN3, HN4, HN5,
HN6, 015B, SIHN-5B, 011A, SIHN-11B, (head and neck
cancer) were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM). PJ41 and PJ34 (head and neck can-
cer) were cultured in Iscove’s Modified Eagle’s Medium
(IMEM, Gibco, Invitrogen, Paisley, UK) and Jurkat
(leukemia) were cultured in Roswell Park Memorial In-
stitute media (RPMI). DMEM and IMEM were supple-
mented with 5% (v/v) FCS and RPMI with 10% (v/v)
FCS (PAA, Pasching, Austria). All media contained 1%
(v/v) L-glutamine and 0.5% (v/v) penicillin/streptomycin
and cells were kept at 37°C in a humidified atmosphere
containing 10% CO2. All cell lines were obtained from
Dr S Eccles, ICR, UK, except for Jurkat, which was
obtained from Prof. R. Marais, ICR, UK.
Oncolytic Reovirus
Reovirus (Dearing Type 3) was obtained from Oncolytics™
Biotech Inc. (Calgary, Canada) and stored at −80°C. Neat
stocks were in phosphate-buffered Saline (PBS) and 1:10
working dilutions were stored in DMEM containing 2%
(v/v) FCS, 1% (v/v) glutamine and 0.5% (v/v) penicillin/
streptomycin (plating media). New stocks of working
dilutions were made periodically and titred by standard
Tissue Culture Infectious Dose 50 (TCID50) assay on
L929 cells, as described previously [39].
Reagents
Recombinant human EGF (R&D Systems, Abingdon,
UK), along with the EGFR inhibitors Iressa/Gefitinib
(Biaffin, Kassel, Germany) Tyrphostin-AG99 (Calbiochem,
Merck Chemicals, Nottingham, UK) and EGFR blocking
antibody ICR62 (from Dr Sue Eccles, ICR, UK) were used
in cell kill assays, western blot and one-step growth curve
assays. MEK1/2 inhibitor U0126, PI3K inhibitor LY294002,
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http://www.biomedcentral.com/1471-2407/12/368p38 MAPK inhibitor SB202190 MEK1/2 and MEK 5 in-
hibitor PD184352 (all from Calbiochem, Merck Chemi-
cals, Nottingham, UK) and Wortmannin (Sigma-Aldrich,
Gillingham, UK) were used in cell kill and western blot
analyses. ZVAD (R&D Systems, Abingdon, UK), chymo-
trypsin (CHT, Roche Applied Science, Burgess Hill, UK)
and 2-aminopurine (2AP, Sigma Aldrich, Gillingham, UK)
were used in cell kill assays. Camptothecin, (Sigma-
Aldrich, Gillingham, UK) was used as a positive control
for the induction of apoptosis in western blots.
Cell survival experiments
Cells were seeded at 5x103 in 96-well plates and incu-
bated at 37°C for 24hrs before experimental conditions
were applied. Where used, cells were treated with
antibodies, inhibitors and ligands for 1–2 hrs before in-
fection. Additional plating media was added to the wells
2-24hrs after infection and cell survival was assessed 96
hrs post-infection by MTT assay as described previously
[10]. Reovirus IC50 values were determined by
interpolation from a sigmoidal dose response curve fit of
the log transformed survival data, derived using GraphPad
Prism version 4.0c for Mac OS X (GraphPad Software Inc.
San Diego, USA).
ISVPs and cores
Reovirus stocks were treated with a final concentration
of 10μg/ml sequencing grade CHT reconstituted in 1
mM HCl plus sequencing buffer, as per manufacturer’s
instructions. Following digestion the CHT was neutra-
lised with FCS and equal volumes of virus were analysed
by western blot (see below). Proteins were detected
using polyclonal anti-reovirus goat serum (Oncolytics
Biotech Inc). Rabbit anti-goat HRP-conjugated antibody
(Pierce, Perbio, Aalst, Belgium) was used for secondary
detection. For cell kill analyses ISVP and core particles
were created as above, diluted out in plating media and
used to infect cells. Survival was analysed as described
above.
Assessment of cell surface EGFR
Cells were cultured in T175 flasks, harvested and 1×106
cells stained with ICR62 for 1 hr at 4°C. Primary anti-
body binding was detected using F(ab’)2 rabbit anti-rat
FITC conjugated IgG (Serotec, Oxford, UK). Staining
was analysed using a FACSCalibur machine (Becton
Dickinson, Oxford, UK).
Western blots
Cells were incubated at 37°C for 24hrs before treatment
with inhibitors. Monolayers were washed twice with PBS
and scraped into 200 μl of lysis buffer (LB), supplemen-
ted with complete mini protease inhibitor cocktail
tablets (Roche Applied Science, Gillingham, UK) forEGFR and ERK1/2 detection, phosphatase and protease
inhibitors, as previously described for AKT analysis [10],
and 10 μg/ml TLCK, 1 mM PMSF and a 1:100 dilution
of protease cocktail I (all Sigma-Aldrich, Gillingham,
UK) for pro-caspase 3 assay. Lysates were loaded into
pre-cast sodium dodecyl sulfate-polyacrylamide (SDS-
PAGE) gels, either Precise Protein gels (Pierce, Perbio,
Aalst, Belgium) or NuPage Novex Bis-Tris gels (Invitro-
gen, Paisley, UK). Following electrophoresis proteins
were transferred to polyvinylidene fluoride (PVDF)
membranes and probed with specific primary antibodies
as follows: murine anti-EGFR (Sigma-Aldrich, Gillingham,
UK), rabbit anti-pY1068 EGFR (Invitrogen, Paisley, UK)
rabbit anti-p44/42 MAPK, rabbit anti-phospsho-p44/42
MAPK, rabbit anti-AKT, rabbit anti-phospho-AKT, rabbit
anti-EIF2α, rabbit anti-caspase 3 (all Cell Signalling Tech-
nology, Danvers, USA). Incubations with primary anti-
bodies were followed by secondary labelling using sheep
anti-mouse HRP (Amersham Biosciences, GE Healthcare,
Amersham, UK) or goat anti-rabbit (Santa Cruz Biotech-
nology, Santa-Cruz, USA). SuperSignal West Pico Chemi-
luminescent Substrate (Pierce, Perbio, Aalst, Belgium) was
used according to the manufacturers instructions for
detection. Membranes were stripped between antibody
staining procedures in Restore Western Blot Stripping
Buffer (Pierce, Perbio, Aalst, Belgium) for 15mins at 37°C.
Murine anti-α tubulin or anti-α tubulin (Sigma-Aldrich,
Gillingham, UK), murine anti-GAPDH (Novus Biologicals,
Littleton, USA) or rabbit anti-β actin (Cell Signalling
Technology, Danvers, USA) were used for loading
controls.
Active Ras Pull-Down and Detection
Cells were grown so they were sub-confluent in T75
flasks prior to harvesting, processing and western blot-
ting for Ras small GTPase activation using the Active
Ras Pull-Down and Detection Kit (Thermo Scientific,
Rockford, IL, USA). Experiments were performed per
protocol according to the manufacturer’s instructions.
One-step viral growth assays
Cells were seeded at 1×105 in 24 well plates and treated
o/n at 37°C with plating media alone, or plating media
containing EGFR ligand/inhibitors. The following day
cells were infected with reovirus for 2 hrs. Monolayers
were washed once with PBS and the ligand/inhibitors
replaced. Cells were scraped into the supernatant and
harvested at time points post-infection, freeze-thawed
three times and titred by TCID50 assay on L929 cells, as
described previously [39].
p38MAPK ELISA
Cells were plated at 5 × 105 in 6 cm dishes. Cells were
treated with SB202190 (10 μM) for 2 hours, harvested,
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http://www.biomedcentral.com/1471-2407/12/368and analysed for phospho-p38 (Surveyor IC: Human/
Mouse/Rat Phospho-p38/ (T180/Y182) immunoassay
#SUV869, R&D Systems, Minneapolis, USA). Experi-
ments were performed according to the protocol pro-
vided for the assay by the manufacturers.
Interferon ELISA
Cal27, HN3, HN5 and SIHN-5B cells plated at 1 × 106
in 10 cm dishes were treated with reovirus at an MOI of
5, or left untreated. Cells were incubated for 24 hours
and supernatants were collected and spun down to re-
move cell debris. Samples were stored at −20°C until
analysis for alpha, beta and gamma interferon by ELISA.
IFN-α was analysed using match-paired antibodies from
Mabtech, IFN-γ with match-paired antibodies from BD
Biosciences and IFN-β using a kit from PBL Interferon
Source according to the manufacturer’s instructions.
Data were read on a Multiskan EX plate reader (Thermo
Scientific) at 405 nm using Ascent software.
JAM-1 FACS Analysis
Cells were harvested with trypsin, pelleted and resus-
pended in FACS buffer (1% FCS in PBS). 1 × 105 cells in
100 μL were stained with 2 μL of JAM-A antibody
(1H2A9, Santa Cruz, USA) or isotype control (mouse
IgG2b-PE, Santa Cruz) and incubated for 30 minutes at
4°C. One millilitre of FACS buffer was added and cells
were pelleted. Pellets were either resuspended in 500 μL
PBS and analysed within an hour using a FACSCalibur
machine (Becton Dickinson, Oxford, UK), or fixed in 1%
paraformaldehyde for analysis within 5 days.
Statistics
The data on EGFR status and reovirus cell killing were not
normally distributed. Therefore Spearman’s rank correlation
was used to test the correlation between EGFR status and
reovirus cytotoxicity. A non-parametric test (Wilcoxon
signed rank test) was used for testing of significance when
evaluating the effects of agonists and inhibitors of the
RGFR/Ras pathway on reovirus-induced cytotoxicity.
Additional files
Additional file 1: Junctional Adhesion Molecule-1 (JAM1)
expression is similar in cell lines with widely differing IC50 values
for reovirus. A. HN5, B. HN3, C. Cal27, D. SIHN-5B. Mean fluorescence
intensity values are indicated and are representative of at least 3 repeat
experiments.
Additional file 2: Table S1. Cell lines ranked according to their EGFR
expression by FACS and western analysis for either total or phospho-
EGFR.
Additional file 3: EGFR ranked (1 = EGFR low, 9 = EGFR high) by
FACS (median fluorescence levels) and western blot (densitometry)
correlate (R2 = 0.90).
Additional file 4: EGFR ranked by median fluorescence levels on
FACS (1 = EGFR low, 9 = EGFR high) and by densitometry forphospho-tyr1068 EGFR western blot (1 = pEGFR low, 9 = pEGFR
high) do not correlate (R2 = 0.22).
Additional file 5: Stimulation or inhibition of EGFR signalling does
not affect reovirus cytotoxicity in SIHN-5B cells. Cells were treated for
1 hr with 200nM epidermal growth factor (EGF), 400nM anti-EGFR
antibody (ICR62), 1μM Iressa or 100μM Tyrphostin AG99 (Tyrp), then
either lysed, resolved on 8% Precise Protein Gels and probed for total
EGFR, phospho-Tyr1068 EGFR and GAPDH or α-tubulin as loading
controls, or infected with reovirus at 1.9×109 TCID50/ml and assayed for
cell survival by MTT. Reovirus was diluted as follows: 1:64000 (20%) 1:8000
(50%) and 1:500 (80%). A. EGF stimulation does not increase reoviral
cytotoxicity. B, C, D. ICR62-, gefitinib- (Iressa) and Tyrphostin-mediated
inhibition of EGFR did not inhibit reoviral cytotoxicity. Means are
calculated from 3 independent experiments and error bars represent
SEMs. E. Western blot analysis showing effect of EGF, ICR62, Gefitinib
(Iressa) and Tyrphostin on EGFR signaling.
Additional file 6: Stimulation or inhibition of EGFR signalling does
not affect reovirus cytotoxicity in HN3 cells. Cells were treated for 1
hr with 200nM epidermal growth factor (EGF), 400nM anti-EGFR antibody
(ICR62), 1μM Iressa or 100μM Tyrphostin AG99 (Tyrp), then either lysed,
resolved on 8% Precise Protein Gels and probed for total EGFR, phospho-
Tyr1068 EGFR and GAPDH or α-tubulin as loading controls, or infected
with reovirus at 1.9×109 TCID50/ml and assayed for cell survival by MTT at
96 hours post-infection. Reovirus was diluted as follows: 1:32000 (20%)
1:2000 (50%) and 1:100 (80%). A. EGF stimulation does not increase
reoviral cytotoxicity. B, C, D. ICR62-, gefitinib- (Iressa) and Tyrphostin-
mediated inhibition of EGFR did not inhibit reoviral cytotoxicity. Means
are calculated from 3 independent experiments and error bars represent
SEMs. E. Western blot analysis showing effect of EGF, ICR62, Gefitinib
(Iressa) and Tyrphostin on EGFR signaling.
Additional file 7: Stimulation or inhibition of EGFR signalling does
not affect reovirus cytotoxicity in HN5 cells. Cells were treated for 1
hr with 200nM epidermal growth factor (EGF), 400 nM anti-EGFR
antibody (ICR62), 1 μM Iressa or 100 μM Tyrphostin AG99 (Tyrp), then
either lysed, resolved on 8% Precise Protein Gels and probed for total
EGFR, phospho-Tyr1068 EGFR and GAPDH or α-tubulin as loading
controls, or infected with reovirus at 1.9×109 TCID50/ml and assayed for
cell survival by MTT at 96 hours post-infection. Reovirus was diluted as
follows: 1:200 (20%) 1:100 (50%) and 1:50 (80%). A. EGF stimulation does
not increase reoviral cytotoxicity. B, C, D. ICR62-, gefitinib- (Iressa) and
Tyrphostin-mediated inhibition of EGFR did not inhibit reoviral
cytotoxicity. Means are calculated from 3 independent experiments and
error bars represent SEMs. E. Western blot analysis showing effect of EGF,
ICR62, Gefitinib (Iressa) and Tyrphostin on EGFR signaling.
Additional file 8: The EGFR inhibitors ICR62 and Iressa are active in
the context of stimulation by EGF. Cells were treated with 400nM
ICR62, 5mM Iressa or 10uM Tryphostin for 2 hours prior to treatment with
200nM EGF. Cell were then harvested an hour later for analysis of EGFR
by western blot.
Additional file 9: Reovirus grows at the same rate in EGFR inhibited
SCCHN cells as in untreated cells. (A) Cal27, (B) SIHN 5B, (C) HN3 and
(D) HN5, were treated overnight with 1 μM Iressa then infected with
reovirus (MOI 10) using viral stocks at 1.2×1010 TCID50/ml. Iressa was
replaced 2 hrs post infection. Cells and supernatants were harvested at
the times indicated for TCID50 titration on L929 cells. Means are from at
least 2 independent experiments and error bars represent SEMs.
Additional file 10: Reovirus grows at the same rate in reovirus
sensitive or resistant cells. Cal27, SIHN 5B HN3 and HN5 infected
with reovirus (MOI 10) using viral stocks at 1.9×109 TCID50/ml. Cells
and supernatants were harvested at the times indicated for TCID50
titration on L929 cells. Means are from at least 2 independent
experiments and error bars represent SEMs.
Additional file 11: MEK, PI3-K or p38MAPK inhibition does not
affect reovirus cytotoxicity in SIHN-5B cells. Cells were inhibited for 2
hrs with 2 μM (PD2) or 10 μM (PD10) PD184352, 10 μM U0126 (U), 10 μM
SB202190 (SB), 10 μM LY294003 (LY) or 1 μM wortmannin (wort).
Monolayers were then either lysed, resolved on 8% Precise Protein Gels
(MAPK) or 10% NuPage Novex Bis Tris gels (PI3-K) and probed for total
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GAPDH or β-actin as loading controls, or infected with reovirus at
1.2×1010 TCID50/ml (PD, SB and LY) or 7.8×10
8 TCID50/ml (wort) and
assayed for cell survival by MTT. p38MAPK target knock-down was
confirmed by ELISA. Reovirus was diluted at 1:6000 for 50% cell kill. A, B.
MAPK inhibition. C, D. p38MAPK inhibition. E, F. PI3K inhibition. Means
are calculated from at least 3 independent experiments and error bars
represent SEMs.
Additional file 12: MEK, PI3-K or p38MAPK inhibition does not
affect reovirus cytotoxicity in HN3 cells. Cells were inhibited for 2 hrs
with 2 μM (PD2) or 10 μM (PD10) PD184352, 10 μM U0126 (U), 10 μM
SB202190 (SB), 10 μM LY294003 (LY) or 1 μM wortmannin (wort).
Monolayers were then either lysed, resolved on 8% Precise Protein Gels
(MAPK) or 10% NuPage Novex Bis Tris gels (PI3-K) and probed for total
ERK1/2, phosho-Thr202 ERK1/2, total AKT, phospho-Ser473 AKT and
GAPDH or β-actin as loading controls, or infected with reovirus at
1.2×1010 TCID50/ml (PD, SB and LY) or 7.8×10
8 TCID50/ml (wort) and
assayed for cell survival by MTT at 96 hours post-infection. p38MAPK
target knock-down was confirmed by ELISA. Reovirus was diluted at
1:2000 for 50% cell kill. A, B. MAPK inhibition. C, D. p38MAPK inhibition. E,
F. PI3K inhibition. Means are calculated from at least 3 independent
experiments and error bars represent SEMs.
Additional file 13: MEK, PI3-K or p38MAPK inhibition does not
affect reovirus cytotoxicity in HN5 cells. Cells were inhibited for 2 hrs
with 2 μM (PD2) or 10 μM (PD10) PD184352, 10 μM U0126 (U), 10 μM
SB202190 (SB), 10 μM LY294003 (LY) or 1 μM wortmannin (wort).
Monolayers were then either lysed, resolved on 8% Precise Protein Gels
(MAPK) or 10% NuPage Novex Bis Tris gels (PI3-K) and probed for total
ERK1/2, phosho-Thr202 ERK1/2, total AKT, phospho-Ser473 AKT and
GAPDH or β-actin as loading controls, or infected with reovirus at
1.2×1010 TCID50/ml (PD, SB and LY) or 7.8×10
8 TCID50/ml (wort) and
assayed for cell survival by MTT at 96 hours post-infection. p38MAPK
target knock-down was confirmed by ELISA. Reovirus was diluted at 1:100
for 50% cell kill. A, B. MAPK inhibition. C, D. p38MAPK inhibition. E, F.
PI3K inhibition. Means are calculated from at least 3 independent
experiments and error bars represent SEMs.
Additional file 14: Reovirus in combination with PD184352 is
synergistic. Cal27, HN3, HN5 SIHN5b were plated at 5×103/ 96 well dish
and treated the following day with 200 μl of 2x, 1x, 0.5x calculated IC50
doses of reovirus, PD184352, or the agents in combination. Cells were
analysed for cell survival 96 hours later by MTT assay at 96 hours post-
infection. Data are derived from 2 independent experiments ± SEM. A.
Interaction between the treatment combinations was assessed using the
method of Chou and Talalay [34]. Combination index (CI) values were
calculated where CI <0.9 is classed as synergy, 0.9-1.1 is additive and >1.1
is antagonistic. B. Representative CI values for the combination of
reovirus with PD184352 for Cal27, HN3, HN5 and SIHN5b.
Additional file 15: L929, SIHN11b, HN3, HN5 and PJ41 cells were
seeded at 1 × 106 in 10 cm dishes, treated the following day with
reovirus and were fixed with 10% formalin at room temperature for
4–8 hours then harvested and centrifuged at 1200 rpm for 5
minutes. The remaining pellet was resuspended in sterile DEPC
water before analysis by immunocytochemistry staining for p-PKR
(by G. Nuovo).
Additional file 16: Interferon response does not predict reovirus
sensitivity. Cal27, HN3, HN5 SIHN5b were plated at 1×106/10 cm dish
and the following day treated with reovirus at an MOI of 5 (reo), or left
untreated (Un). Cells were incubated for 24 hours and the the
supernatants were harvested, spun down at 1200 rpm for 4 minutes to
remove cells and debris, and the supernatant transferred to a fresh tube
and stored at −20°C. Samples were analysed in triplicate for interferons
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